Outcome and influence of the malformative syndrome extent, the use of androgens before transplantation, and of T-cell depletion on the 3-year overall survival.

(A) 3-year outcome of the 69 FA patients transplanted with HLA-matched unrelated donors. (B) Effect of the malformative syndrome extent. Patients with a limited malformative syndrome (< 3 anatomic sites) had a 3-year survival of 44% versus 14% if the syndrome was extensive (≥ 3 anatomic sites) (P = .01, log-rank test). (C) Effect of pretransplant androgen therapy. Patients who did not receive androgen therapy had a 3-year survival rate of 49% versus 21% if they had received androgen therapy (P < .03, log-rank test). (D) Effect of T-cell depletion. Patients who received a T-cell–depleted transplant had a 3-year survival of 44% versus 27% if the graft was not T-cell–depleted (P = .33, log-rank test).